English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Results We found that serum NT-pro BNP levels were not significantly different between study groups (63.9±39.8 pg/ml in prolactinoma group, 47.3±31.2 pg/ml in hyperprolactinemia group and 57.2 ± 28.3 pg/ml in control group, p=0.160). Mean cumulative cabergoline dose (CCD) were calculated as 218.1±252.5 (range 52-1248 mg). However, we did not determine any correlations between serum NT-pro BNP levels and cumulative cabergoline dose, and between serum NT-pro BNP and prolactine levels. There was only a positive correlation between CCD and systolic blood tension (r=0.213, p=0.044).

Serum N-terminal pro brain natriuretic peptide level in patients with prolactinoma who were treated with caborgoline